A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC - Trial NCT06254599
Access comprehensive clinical trial information for NCT06254599 through Pure Global AI's free database. This Phase 3 trial is sponsored by Shouyao Holdings (Beijing) Co. LTD and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 255 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shouyao Holdings (Beijing) Co. LTD
Timeline & Enrollment
Phase 3
May 01, 2024
May 01, 2027
Primary Outcome
Progression-free survival (PFS) assessed by independent radiology review (IRC) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) criteria.
Summary
A phase 3 study to evaluate the efficacy and safety of SY-3505 vs. crizotinib in patients
 with ALK-positive non-small cell lung cancer who had not received prior systemic therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06254599
Non-Device Trial